Previous close | 120.40 |
Open | 121.79 |
Bid | 122.05 x 300 |
Ask | 122.18 x 200 |
Day's range | 119.43 - 122.34 |
52-week range | 62.55 - 170.47 |
Volume | |
Avg. volume | 3,935,358 |
Market cap | 46.797B |
Beta (5Y monthly) | 1.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CAMBRIDGE, MA / ACCESSWIRE / June 28, 2024 / Moderna, Inc. (Nasdaq:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing ...
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The report delves into the mRNA platform, examining its global competitive landscape and the market presence of key players. It provides a conceptual understanding of mRNA, highlighting its revolutionary approach to medicine and the significant scientific breakthroughs it represents. The introduction of mRNA vaccines is explored, emphasizing
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against ...